Nasus Pharma Ltd
Undisclosed program
Resolved
104days ago
Catalyst readout · Mar 25, 2026
What's at stake
A key catalyst for Undisclosed program (its lead indication) is expected Mar 25, 2026.
Primary source
· SEC 6-K
verified 14h ago
“the Company has filed its Annual Report on Form 20-F for the year ended December 31, 2025, and provided a business update highlighting recent Phase 2 results for NS002 and upcoming clinical milestones.”